Korean J Lab Med.  2008 Dec;28(6):444-448. 10.3343/kjlm.2008.28.6.444.

Two Cases of Vancomycin-intermediate Staphylococcus aureus Isolated from Joint Tissue or Wound

• Hong KH
• Park JS
• Kim EC

• KMID: 1781579
• DOI: http://doi.org/10.3343/kjlm.2008.28.6.444

Abstract

Since its first isolation in 1997, vancomycin-intermediate Staphylococcus aureus (VISA) has been a clinical concern because it may lead to treatment failure. Up to the present, there were two reports of clinical VISA cases in Korea. We now report two additional cases of VISA with the minimum inhibitory concentration (MIC) of 4 microgram/mL. The first patient was a 59 yr-old man who had undergone total hip replacement arthroplasty in 1999 due to avascular necrosis of femur heads. He had recurrent episodes of infected hip caused by methicillin-resistant Staphylococcus aureus (MRSA) and was treated with vancomycin. He underwent replacement operation of prosthesis. Cultures of joint fluid and joint tissue grew S. aureus. Vancomycin MIC as determined by a broth microdilution method was 4 microgram/mL for the both isolates. The patient was treated with high enough doses of vancomycin to maintain serum trough concentrations at 20-25 microgram/mL for 52 days and was discharged. The second patient was a 57 yr-old man with diabetes. He lost consciousness from drinking. After recovery of consciousness, he was diagnosed with aspiration pneumonia. MRSA and Acinetobacter baumannii were cultured from sputum and the patient was treated with vancomycin and meropenem. During hospitalization, bed sores developed in his ankle and back. A wound culture from the sore grew S. aureus with vancomycin MIC of 4 microgram/mL. Since infection was localized, systemic antibiotics did not seem necessary, and the patient was transferred to another hospital for isolation and management.

Keyword

Vancomycin intermediate Staphylococcus aureus; VISA; Korea

MeSH Terms

Acinetobacter Infections/drug therapy
Acinetobacter baumannii/isolation & purification
Anti-Bacterial Agents/pharmacology/*therapeutic use
Humans
Joints/microbiology
Male
Methicillin-Resistant Staphylococcus aureus/*isolation & purification
Microbial Sensitivity Tests
Middle Aged
Pressure Ulcer/microbiology
Staphylococcal Infections/*drug therapy
Thienamycins/pharmacology/therapeutic use
Vancomycin/pharmacology/*therapeutic use
*Vancomycin Resistance

Reference

1.Hidayat LK., Hsu DI., Quist R., Shriner KA., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006. 166:2138–44.

2.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement, M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute;2006.

3.Kim MN., Pai CH., Woo JH., Ryu JS., Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol. 2000. 38:3879–81.

4.Kim HB., Lee YS., Kim BS., Cha JO., Kwon SU., Lee HJ, et al. Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 microg/ml in Korea. Microb Drug Resist. 2006. 12:33–8.

5.Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Seventh Edition, M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute;2006.

6.Chang S., Sievert DM., Hageman JC., Boulton ML., Tenover FC., Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003. 348:1342–7.

7.Neugen M., Pettyjohn R., Sahm DF. Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA). http://www.narsa.net/. (Updated on Jul. 2008.

8.Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006. 12(S):S16–23.

9.Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001. 1:147–55.

10.Gemmell CG., Edwards DI., Fraise AP., Gould FK., Ridgway GL., Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006. 57:589–608.

11.Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy. 2007. 27:227–49.

12.Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection. 2004. 32:315–27.

13.Centers for Disease Conrol and Prevention. http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_labFAQ.htmL. (Updated on Apr. 2006.

14.Tenover FC., Lancaster MV., Hill BC., Steward CD., Stocker SA., Hancock GA, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol. 1998. 36:1020–7.